Atea Pharmaceuticals

Overview

Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on oral antiviral drug development using nucleos(t)ide chemistry, virology, and medicinal chemistry. Its programs target single-stranded RNA viruses with the goal of discovering, developing and, if approved, commercializing next-generation antivirals.

Lead programs

HCV — bemnifosbuvir + ruzasvir

• Regimen: pan-genotypic, protease-inhibitor–free fixed-dose combination tablet (bemnifosbuvir 275 mg + ruzasvir 90 mg); two tablets daily (total daily dose 550 mg bemnifosbuvir / 180 mg ruzasvir).
• Phase 3 program: two global trials — C-BEYOND (US/Canada) and C-FORWARD (outside North America).
  • Design: open-label, active-comparator non-inferiority vs sofosbuvir/velpatasvir (SOF/VEL).
  • Dosing and endpoints: non-cirrhotic patients receive 8 weeks; patients with compensated cirrhosis receive 12 weeks. Primary endpoint is sustained virologic response at week 24 (SVR24), assessed in mITT for C-BEYOND and per-protocol for C-FORWARD.
  • Enrollment: C-BEYOND fully enrolled with over 880 patients; C-FORWARD actively enrolling with about 880 patients.
  • Timing: topline results expected mid-2026 (C-BEYOND) and end-2026 (C-FORWARD). NDA submission planned for March 2027 in the US; EMA MAA to follow.
• Phase 2 data: 275 patients treated with the eight-week regimen; SVR12 rates up to 98% in adherent non-cirrhotic patients. Program demonstrated pan-genotypic activity, a favorable drug–drug interaction profile, and dosing that can be administered with or without food.

HEV — AT-587

• Status: IND/CTA-enabling studies ongoing. First-in-human Phase 1 (single- and multiple-dose arms in healthy subjects) planned for mid-2026 to determine dose and safety.
• Objective: develop a direct-acting antiviral for chronic HEV infection in immunocompromised patients. Preclinical data show potent antiviral activity and favorable safety signals.

Discovery efforts

• Ongoing assessment of additional nucleos(t)ide-related compounds and other antiviral candidates from internal libraries for potential future development.

Commercialization, manufacturing and collaborations

• Strategy: intends to retain global development rights to its product candidates and may enter collaborations to access commercialization resources and geographic expertise.
• US commercialization: may partner for US sales and managed-care access; the company currently has no internal US commercial infrastructure.
• Outside the US: commercialization is expected to be conducted by third-party collaborators.
• Manufacturing: relies on contract manufacturing organizations (CMOs); does not own or operate manufacturing facilities. The company has started manufacturing commercial launch supply in quantities intended to support an initial launch if approved.
• Merck license for ruzasvir:
  • Upfront payment: $25.0 million
  • Development/regulatory milestones: up to $135.0 million
  • Sales-based milestones: up to $300.0 million
  • Royalties: tiered (high single digits to mid-teens, subject to adjustments)
  • Termination: either party may terminate for breach or insolvency; certain termination scenarios transfer rights to Merck for specified patents and know-how.

Intellectual property

• As of March 1, 2026, the company is the sole owner of 17 patent families covering AT-511 (bemnifosbuvir), related compounds, compositions, methods of use, and manufacturing processes.
• Worldwide portfolio includes more than 300 pending or granted patent filings, including 24 issued US patents and 12 US non-provisional applications, plus more than 250 foreign patents granted or pending.
• Ruzasvir is covered by an exclusive license from Merck for composition of matter, preparation processes, and formulations; related US and foreign patents have expiration timelines roughly in the 2034–2039 range depending on the family.
• A patent family covering the bemnifosbuvir/ruzasvir combination includes an issued US patent and related filings with expiration around 2042.
• AT-587 has a patent family with pending PCT/Taiwan applications and expected expiration around 2046 if issued and enforceable.

Competition and market context

• HCV: multiple approved oral DAA regimens exist (e.g., Epclusa, Mavyret, Harvoni, Vosevi, Zepatier). Atea positions its regimen as a short, 8-week (non-cirrhotic) or 12-week (cirrhotic) pan-genotypic, protease-inhibitor–free option with low drug–drug interactions to simplify treatment.
• HEV: no approved direct-acting antivirals for HEV in most markets. Current management relies on reducing immunosuppression and ribavirin, which can have substantial adverse events. AT-587 is intended to be the first DAA option for chronic HEV in immunocompromised patients if approved.

Financial snapshot (selected)

• Revenue: no commercial product revenue to date.
• Operating expenses: $180.9 million for the year ended December 31, 2025; $193.0 million for 2024.
• Net loss: $158.3 million for the year ended December 31, 2025.
• Accumulated deficit: $522.6 million as of December 31, 2025.
• The company reports substantial ongoing financing needs and may require additional capital.
• Share repurchase program: board authorized up to $25.0 million; completed by December 31, 2025, totaling $25.0 million and 7,673,792 shares repurchased.

Employees and corporate structure

• Employees (as of March 4, 2026): 55 full-time employees; 19 hold MD/PhD/PharmD degrees; 38 are engaged in research and development.
• Headquarters: Boston, Massachusetts.
• Subsidiary: Atea Pharmaceuticals Securities Corporation is a wholly owned Massachusetts subsidiary.

Company focus and execution risks

• The company is concentrated on advancing bemnifosbuvir + ruzasvir through Phase 3 for HCV and AT-587 for HEV.
• Key dependencies include third-party manufacturing, contract research, regulatory approvals, financing, and strategic collaborators for commercialization.
• Profitability depends on successful development, regulatory approval, manufacturing at scale, and effective commercialization, potentially in partnership with third parties.

Key milestones and timelines

• Phase 3 topline results: C-BEYOND mid-2026; C-FORWARD end-2026.
• AT-587 first-in-human Phase 1: planned mid-2026.
• NDA submission for HCV: planned March 2027 (US); EMA MAA to follow.